Red-Flag Reference

Three levels of urgency

Get emergency help now

• Swelling of the face, lips, tongue or throat, trouble breathing or swallowing, or fainting with a very rapid heartbeat: a possible serious allergic reaction.

  Sources · checked September 2026

  • US Food and Drug Administration. FOUNDAYO (orforglipron) tablets: Prescribing Information and Medication Guide. Eli Lilly and Company; revised 07/2026 (Reference ID 5842935). Drugs@FDA. Boxed Warning; sections 5.1 to 5.9, 6.1, 13.1 and 17; Medication Guide.
  • US Food and Drug Administration. SAXENDA (liraglutide) injection: Prescribing Information and Medication Guide. Novo Nordisk; revised 02/2026 (Reference ID 5751134). Drugs@FDA. Sections 5.1, 5.5 and 6.1; Medication Guide.

• Severe pain in the stomach area that will not go away, sometimes felt through to the back, with or without vomiting: possible pancreatitis. The labels say to stop the medicine.

  Sources · checked September 2026

  • US Food and Drug Administration. WEGOVY (semaglutide) injection and tablets: Prescribing Information and Medication Guide. Novo Nordisk; revised 03/2026 (Reference ID 5766092). Drugs@FDA. Boxed Warning; sections 4, 5.1 to 5.10, 6.1 and 17; Medication Guide.
  • US Food and Drug Administration. ZEPBOUND (tirzepatide) injection: Prescribing Information and Medication Guide. Eli Lilly and Company; revised 08/2026 (Reference ID 5863109). Drugs@FDA. Boxed Warning; sections 5.1 to 5.9, 6.1 and 17; Medication Guide.
  • US Food and Drug Administration. FOUNDAYO (orforglipron) tablets: Prescribing Information and Medication Guide. Eli Lilly and Company; revised 07/2026 (Reference ID 5842935). Drugs@FDA. Boxed Warning; sections 5.1 to 5.9, 6.1, 13.1 and 17; Medication Guide.

• Sudden loss of vision, or eyesight that worsens quickly.

  Sources · checked September 2026

  • World Health Organization. The use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION). Medical product alert, 27 June 2025. Reports the European Medicines Agency’s conclusion that NAION is a very rare side effect, potentially affecting up to 1 in 10,000 users.

• Thoughts of harming yourself. In the United States, call or text 988.

  Checked September 2026.

Call your prescriber today

• Vomiting or diarrhea that does not stop, or you cannot keep fluids down.

  Sources · checked September 2026

  • US Food and Drug Administration. FOUNDAYO (orforglipron) tablets: Prescribing Information and Medication Guide. Eli Lilly and Company; revised 07/2026 (Reference ID 5842935). Drugs@FDA. Boxed Warning; sections 5.1 to 5.9, 6.1, 13.1 and 17; Medication Guide.
  • US Food and Drug Administration. SAXENDA (liraglutide) injection: Prescribing Information and Medication Guide. Novo Nordisk; revised 02/2026 (Reference ID 5751134). Drugs@FDA. Sections 5.1, 5.5 and 6.1; Medication Guide.

• Pain in the upper stomach with fever, yellowing of the skin or eyes, or clay-colored stools: possible gallbladder trouble.

  Sources · checked September 2026

  • US Food and Drug Administration. ZEPBOUND (tirzepatide) injection: Prescribing Information and Medication Guide. Eli Lilly and Company; revised 08/2026 (Reference ID 5863109). Drugs@FDA. Boxed Warning; sections 5.1 to 5.9, 6.1 and 17; Medication Guide.
  • US Food and Drug Administration. FOUNDAYO (orforglipron) tablets: Prescribing Information and Medication Guide. Eli Lilly and Company; revised 07/2026 (Reference ID 5842935). Drugs@FDA. Boxed Warning; sections 5.1 to 5.9, 6.1, 13.1 and 17; Medication Guide.

• Shaking, sweating, confusion, fast heartbeat or blurred vision if you also take insulin or a sulfonylurea: possible low blood sugar.

  Sources · checked September 2026

  • US Food and Drug Administration. FOUNDAYO (orforglipron) tablets: Prescribing Information and Medication Guide. Eli Lilly and Company; revised 07/2026 (Reference ID 5842935). Drugs@FDA. Boxed Warning; sections 5.1 to 5.9, 6.1, 13.1 and 17; Medication Guide.

• A racing or pounding heartbeat at rest that lasts for several minutes.

  Sources · checked September 2026

  • US Food and Drug Administration. SAXENDA (liraglutide) injection: Prescribing Information and Medication Guide. Novo Nordisk; revised 02/2026 (Reference ID 5751134). Drugs@FDA. Sections 5.1, 5.5 and 6.1; Medication Guide.

Mention at your next visit

• A lump or swelling in the neck, hoarseness that will not go away, or trouble swallowing.

  Sources · checked September 2026

  • US Food and Drug Administration. ZEPBOUND (tirzepatide) injection: Prescribing Information and Medication Guide. Eli Lilly and Company; revised 08/2026 (Reference ID 5863109). Drugs@FDA. Boxed Warning; sections 5.1 to 5.9, 6.1 and 17; Medication Guide.
  • US Food and Drug Administration. FOUNDAYO (orforglipron) tablets: Prescribing Information and Medication Guide. Eli Lilly and Company; revised 07/2026 (Reference ID 5842935). Drugs@FDA. Boxed Warning; sections 5.1 to 5.9, 6.1, 13.1 and 17; Medication Guide.

• Changes in vision if you have type 2 diabetes.

  Sources · checked September 2026

  • US Food and Drug Administration. FOUNDAYO (orforglipron) tablets: Prescribing Information and Medication Guide. Eli Lilly and Company; revised 07/2026 (Reference ID 5842935). Drugs@FDA. Boxed Warning; sections 5.1 to 5.9, 6.1, 13.1 and 17; Medication Guide.

• Feeling dizzy or light-headed, which can be a sign of low blood pressure, especially if you take blood pressure medicine.

  Sources · checked September 2026

  • US Food and Drug Administration. FOUNDAYO (orforglipron) tablets: Prescribing Information and Medication Guide. Eli Lilly and Company; revised 07/2026 (Reference ID 5842935). Drugs@FDA. Boxed Warning; sections 5.1 to 5.9, 6.1, 13.1 and 17; Medication Guide.

From the FDA drug labels, checked September 2026; sources in chapter 9.